{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=QS21&page=2", "query": { "intervention": "QS21", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=QS21&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-22T10:49:52.654Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00001096", "title": "A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 MN rsgp120 and Bivalent AIDSVAX B/E (HIV-1 MN rgp120/A244 rgp120) in Combination With QS-21 With or Without Alum in Healthy HIV-1 Uninfected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "MN rgp120/HIV-1 and A244 rgp120/HIV-1", "type": "BIOLOGICAL" }, { "name": "QS-21", "type": "BIOLOGICAL" }, { "name": "rgp120/HIV-1MN", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 60, "start_date": null, "completion_date": "2000-03", "has_results": false, "last_update_posted_date": "2021-11-04", "last_synced_at": "2026-09-22T10:49:52.654Z", "location_count": 4, "location_summary": "Baltimore, Maryland • Rochester, New York • Nashville, Tennessee + 1 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Rochester", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001096" }, { "nct_id": "NCT00003362", "title": "Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma (Skin)" ], "interventions": [ { "name": "QS21", "type": "BIOLOGICAL" }, { "name": "gp100 antigen", "type": "BIOLOGICAL" }, { "name": "incomplete Freund's adjuvant", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "tyrosinase peptide", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1998-05", "completion_date": "2001-02", "has_results": false, "last_update_posted_date": "2013-06-25", "last_synced_at": "2026-09-22T10:49:52.654Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003362" }, { "nct_id": "NCT00003819", "title": "Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "QS21", "type": "BIOLOGICAL" }, { "name": "TF(c)-KLH conjugate vaccine", "type": "BIOLOGICAL" }, { "name": "Thomsen-Friedenreich antigen", "type": "BIOLOGICAL" }, { "name": "keyhole limpet hemocyanin", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 21, "start_date": "1998-06", "completion_date": "2009-03", "has_results": false, "last_update_posted_date": "2013-03-19", "last_synced_at": "2026-09-22T10:49:52.654Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003819" }, { "nct_id": "NCT06015724", "title": "Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Ductal Adenocarcinoma", "Refractory Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Daratumumab", "type": "DRUG" }, { "name": "KRAS vaccine", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Georgetown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2024-01-31", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-06-30", "last_synced_at": "2026-09-22T10:49:52.654Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06015724" }, { "nct_id": "NCT00960531", "title": "A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Alzheimer Disease" ], "interventions": [ { "name": "ACC-001+ QS21 (3mcg)", "type": "BIOLOGICAL" }, { "name": "ACC-001 (10 mcg) + QS-21", "type": "BIOLOGICAL" }, { "name": "ACC-001+QS-21 (30mcg)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "50 Years to 85 Years" }, "enrollment_count": 160, "start_date": "2009-07", "completion_date": "2013-12", "has_results": true, "last_update_posted_date": "2016-04-01", "last_synced_at": "2026-09-22T10:49:52.654Z", "location_count": 28, "location_summary": "Phoenix, Arizona • Sun City, Arizona • San Francisco, California + 10 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00960531" }, { "nct_id": "NCT01227564", "title": "Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Alzheimer's Disease" ], "interventions": [ { "name": "ACC-001 3 μg/ QS-21 50 μg", "type": "BIOLOGICAL" }, { "name": "ACC-001 10 μg/ QS-21 50 μg", "type": "BIOLOGICAL" }, { "name": "Placebo- Phosphate buffered saline (PBS)", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "50 Years to 80 Years" }, "enrollment_count": 63, "start_date": "2011-02", "completion_date": "2014-02", "has_results": true, "last_update_posted_date": "2016-02-25", "last_synced_at": "2026-09-22T10:49:52.654Z", "location_count": 40, "location_summary": "Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 17 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01227564" }, { "nct_id": "NCT05500417", "title": "Safety and Immunogenicity of CJCV2 With and Without ALFQ", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Campylobacter Infection" ], "interventions": [ { "name": "ALFQ", "type": "DRUG" }, { "name": "CJCV2", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 59, "start_date": "2022-09-13", "completion_date": "2025-01-02", "has_results": true, "last_update_posted_date": "2026-06-15", "last_synced_at": "2026-09-22T10:49:52.654Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05500417" }, { "nct_id": "NCT04268420", "title": "A Trial For The Study of Falciparum Malaria Protein 013 Administered Via Intramuscular Injection in Healthy Adults", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Vaccine Reaction" ], "interventions": [ { "name": "FMP013", "type": "DRUG" }, { "name": "ALFQ", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "U.S. Army Medical Research and Development Command", "sponsor_class": "FED", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 46, "start_date": "2020-03-20", "completion_date": "2023-12", "has_results": false, "last_update_posted_date": "2023-01-10", "last_synced_at": "2026-09-22T10:49:52.654Z", "location_count": 1, "location_summary": "Silver Spring, Maryland", "locations": [ { "city": "Silver Spring", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04268420" }, { "nct_id": "NCT06741072", "title": "BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Kidney Disease, Stage 4", "Chronic Kidney Disease, Stage 5", "EBV-Related Lymphoproliferative Disorder", "EBV-Related Malignant Neoplasm", "Post-Transplant Lymphoproliferative Disorder" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Dulbecco''s Phosphate-Buffered Saline", "type": "DRUG" }, { "name": "Peptide Vaccine", "type": "BIOLOGICAL" }, { "name": "QS21", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 55, "start_date": "2026-06-28", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-07-02", "last_synced_at": "2026-09-22T10:49:52.654Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06741072" }, { "nct_id": "NCT00004249", "title": "Vaccine Therapy Plus QS21 in Treating Patients With Small Cell Lung Cancer That Has Responded to Initial Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "QS21", "type": "BIOLOGICAL" }, { "name": "keyhole limpet hemocyanin", "type": "BIOLOGICAL" }, { "name": "polysialic acid", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1998-08", "completion_date": "2001-11", "has_results": false, "last_update_posted_date": "2013-06-19", "last_synced_at": "2026-09-22T10:49:52.654Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004249" } ] }